FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308398719> ?p ?o ?g. }

• W4308398719 abstract "<h3>Background</h3> The phase 2/3 RELATIVITY-047 clinical trial (NCT03470922) in patients with previously untreated metastatic or unresectable melanoma met its primary endpoint of improved progression-free survival with a combination of nivolumab plus relatlimab (NIVO+RELA) compared with NIVO monotherapy.¹ To better understand the biology underlying combined programmed death-1 (PD-1) and lymphocyte-activation gene 3 (LAG-3) inhibition, a series of exploratory biomarker analyses was performed. Analyses included longitudinal changes in immunomodulatory cytokines, free soluble LAG-3 (sLAG-3), and selected immune-cell markers within tumor biopsies collected at baseline. <h3>Methods</h3> Peripheral blood serum samples collected prior to treatment, and prior to study drug during week 4 and week 8 of treatment, were evaluated for changes in inflammatory cytokines including interferon gamma (IFNγ) and sLAG-3. Baseline tumor samples were collected prior to treatment and were analyzed by immunohistochemistry for LAG-3 (17B4), CD8 (C8/144B), and tumor cell programmed death-ligand 1 (PD-L1) expression (Agilent/Dako PD-L1 28-8 IHC pharmDx).^1–3 Correlative analyses were performed. <h3>Results</h3> Four weeks after treatment initiation, IFNγ levels increased over baseline in both treatment arms (table 1), but increases were significantly larger with NIVO+RELA than with NIVO (fold change 2.17 and 1.54, respectively; <i>P</i> <0.0001). Eight weeks after treatment initiation, sLAG-3 levels were modestly increased with NIVO (fold change 1.12; <i>P</i> <0.001), and significantly decreased with NIVO+RELA (fold change 0.60; <i>P</i> <0.001) (table 2), suggesting RELA-specific target engagement in the combination arm. No significant correlation was observed between baseline sLAG-3 and tissue-based LAG-3 expression in pretreatment tumors (Spearman’s <i>r</i>=0.21). In baseline tumor biopsies, LAG-3 showed moderate correlation with PD-L1 expression (<i>r</i>=0.53) (figure 1). The majority of LAG-3–negative tumors (<1%) were also PD-L1 negative (<1%). PD-L1 expression varied among LAG-3–expressing tumors, with differences observed in the range of PD-L1 expression (high vs low) across LAG-3 subgroups. CD8 levels correlated more strongly with LAG-3 than with PD-L1. Furthermore, patients whose tumors had higher LAG-3 expression (≥1% and ≥5%) had numerically higher median progression-free survival and objective response rates in both the NIVO+RELA and NIVO arms. <h3>Conclusions</h3> These exploratory analyses support the hypothesis that NIVO+RELA enhances immune activation compared with NIVO alone, and that LAG-3 may be a promising biomarker of tumor inflammation. Although LAG-3 alone may not be a useful predictive biomarker for selection of patients with melanoma for NIVO+RELA vs NIVO regimens, further work is required to assess the clinical utility of LAG-3, likely as part of a composite biomarker of immunotherapy susceptibility. <h3>Acknowledgements</h3> Editorial support was provided by Sandra J Page, PhD, of Spark Medica Inc. <h3>Trial Registration</h3> Clinicaltrials. gov. NCT03470922. <h3>References</h3> Tawbi HA <i>et al</i>. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. <i>N Engl J Med</i>. 2022;<b>386</b>:24–34. Johnson L <i>et al</i>. Development of a LAG-3 immunohistochemistry assay for melanoma. <i>J Clin Pathol</i>. 2022;jclinpath-2022-208254. doi:10.1136/jclinpath-2022-208254. Szabo PM <i>et al</i>. Development and performance of a CD8 gene signature for characterizing inflammation in the tumor microenvironment across multiple tumor types. <i>J Mol Diagn.</i> 2021;<b>23</b>:1159–1173. <h3>Ethics Approval</h3> All trial investigators received approval from their respective institutional review boards. The trial was conducted in accordance with the International Council for Harmonisation Good Clinical Practice guidelines, and all patients provided written informed consent before participation. An independent data monitoring committee provided oversight to assess the efficacy and safety profile of relatlimab and nivolumab." @default.
• W4308398719 created "2022-11-11" @default.
• W4308398719 creator A5001281569 @default.
• W4308398719 creator A5010077446 @default.
• W4308398719 creator A5011612015 @default.
• W4308398719 creator A5014494747 @default.
• W4308398719 creator A5020414234 @default.
• W4308398719 creator A5029398339 @default.
• W4308398719 creator A5029619006 @default.
• W4308398719 creator A5034365278 @default.
• W4308398719 creator A5042614329 @default.
• W4308398719 creator A5044394718 @default.
• W4308398719 creator A5057898973 @default.
• W4308398719 creator A5066493892 @default.
• W4308398719 creator A5071777890 @default.
• W4308398719 creator A5077809055 @default.
• W4308398719 creator A5079594267 @default.
• W4308398719 creator A5084967339 @default.
• W4308398719 date "2022-11-01" @default.
• W4308398719 modified "2023-10-18" @default.
• W4308398719 title "606 Biomarker analyses of baseline tumor specimens and on-treatment changes in sera samples of patients enrolled in the RELATIVITY-047 trial to characterize LAG-3 biology" @default.
• W4308398719 doi "https://doi.org/10.1136/jitc-2022-sitc2022.0606" @default.
• W4308398719 hasPublicationYear "2022" @default.
• W4308398719 type Work @default.
• W4308398719 citedByCount "0" @default.
• W4308398719 crossrefType "proceedings-article" @default.
• W4308398719 hasAuthorship W4308398719A5001281569 @default.
• W4308398719 hasAuthorship W4308398719A5010077446 @default.
• W4308398719 hasAuthorship W4308398719A5011612015 @default.
• W4308398719 hasAuthorship W4308398719A5014494747 @default.
• W4308398719 hasAuthorship W4308398719A5020414234 @default.
• W4308398719 hasAuthorship W4308398719A5029398339 @default.
• W4308398719 hasAuthorship W4308398719A5029619006 @default.
• W4308398719 hasAuthorship W4308398719A5034365278 @default.
• W4308398719 hasAuthorship W4308398719A5042614329 @default.
• W4308398719 hasAuthorship W4308398719A5044394718 @default.
• W4308398719 hasAuthorship W4308398719A5057898973 @default.
• W4308398719 hasAuthorship W4308398719A5066493892 @default.
• W4308398719 hasAuthorship W4308398719A5071777890 @default.
• W4308398719 hasAuthorship W4308398719A5077809055 @default.
• W4308398719 hasAuthorship W4308398719A5079594267 @default.
• W4308398719 hasAuthorship W4308398719A5084967339 @default.
• W4308398719 hasBestOaLocation W43083987191 @default.
• W4308398719 hasConcept C121608353 @default.
• W4308398719 hasConcept C126322002 @default.
• W4308398719 hasConcept C143998085 @default.
• W4308398719 hasConcept C167672396 @default.
• W4308398719 hasConcept C203014093 @default.
• W4308398719 hasConcept C203092338 @default.
• W4308398719 hasConcept C204232928 @default.
• W4308398719 hasConcept C2777701055 @default.
• W4308398719 hasConcept C2780030458 @default.
• W4308398719 hasConcept C2781197716 @default.
• W4308398719 hasConcept C535046627 @default.
• W4308398719 hasConcept C55493867 @default.
• W4308398719 hasConcept C71924100 @default.
• W4308398719 hasConcept C86803240 @default.
• W4308398719 hasConcept C8891405 @default.
• W4308398719 hasConcept C90924648 @default.
• W4308398719 hasConceptScore W4308398719C121608353 @default.
• W4308398719 hasConceptScore W4308398719C126322002 @default.
• W4308398719 hasConceptScore W4308398719C143998085 @default.
• W4308398719 hasConceptScore W4308398719C167672396 @default.
• W4308398719 hasConceptScore W4308398719C203014093 @default.
• W4308398719 hasConceptScore W4308398719C203092338 @default.
• W4308398719 hasConceptScore W4308398719C204232928 @default.
• W4308398719 hasConceptScore W4308398719C2777701055 @default.
• W4308398719 hasConceptScore W4308398719C2780030458 @default.
• W4308398719 hasConceptScore W4308398719C2781197716 @default.
• W4308398719 hasConceptScore W4308398719C535046627 @default.
• W4308398719 hasConceptScore W4308398719C55493867 @default.
• W4308398719 hasConceptScore W4308398719C71924100 @default.
• W4308398719 hasConceptScore W4308398719C86803240 @default.
• W4308398719 hasConceptScore W4308398719C8891405 @default.
• W4308398719 hasConceptScore W4308398719C90924648 @default.
• W4308398719 hasLocation W43083987191 @default.
• W4308398719 hasOpenAccess W4308398719 @default.
• W4308398719 hasPrimaryLocation W43083987191 @default.
• W4308398719 hasRelatedWork W2141197908 @default.
• W4308398719 hasRelatedWork W2518309888 @default.
• W4308398719 hasRelatedWork W2904759734 @default.
• W4308398719 hasRelatedWork W2946562078 @default.
• W4308398719 hasRelatedWork W2969738919 @default.
• W4308398719 hasRelatedWork W2979416044 @default.
• W4308398719 hasRelatedWork W2981883049 @default.
• W4308398719 hasRelatedWork W3180780036 @default.
• W4308398719 hasRelatedWork W4291367166 @default.
• W4308398719 hasRelatedWork W4360983034 @default.
• W4308398719 isParatext "false" @default.
• W4308398719 isRetracted "false" @default.
• W4308398719 workType "article" @default.